Rewiring neurotrophic signaling to escape targeted therapy in hepatocellular carcinoma

References

[1] Chen Y,Chen D,Liang Z.et al. Immune checkpoint inhibitors in hepatocellular carcinoma therapy: resistance mechanisms, liver transplantation challenges and management strategies Cancer Drug Resist 2025 8 48 PMC12462397

[2] Qi D,Qin Y,Zhu H,Li Y,Han S. Resistance of first-line targeted drugs in hepatocellular carcinoma: the epigenetic regulation mechanisms Cell Death Dis 2025 16 875 PMC12669607

[3] Sun Y,Luo C,Yang H.et al. Lactylation converts ABHD6 into a mitochondrial regulator that drives lenvatinib resistance in hepatocellular carcinoma Cancer Res 2026 86 2970 89 PMC13266342

[4] Zhang Y,Lin Y,Cai H,Zhou T. EZH2 confers lenvatinib resistance in hepatocellular carcinoma by suppressing ACSL1-Mediated ferroptosis BMC Cancer 2025 25 1638 PMC12551213

[5] Xu,M. , Zheng, Y., Zhao, L., et al. Activation of nerve growth factor signaling limits the response to lenvatinib in hepatocellular carcinoma Signal Transduct Target Ther 2026 11 10 PMC13057041

[6] Ferraguti G,Terracina S,Tarani L.et al. Nerve growth factor and the role of inflammation in tumor development Curr Issues Mol Biol 2024 46 965 89 PMC10888178

[7] Yin T,Wang G,Wang L.et al. Breaking NGF-TrkA immunosuppression in melanoma sensitizes immunotherapy for durable memory T cell protection Nat Immunol 2024 25 268 81 PMC11377935

[8] Balasubramanian K,Fung KM,McNall-Knapp RY,Balsara K. Sustained response to larotrectinib in a pediatric patient with recurrent STRN3::NTRK2 fusion-positive pilocytic astrocytoma CNS Oncol 2025 14 2558455 PMC12498535

[9] Yamazaki H,Sugimori M,Saito A. Larotrectinib efficacy for liver metastases in papillary thyroid carcinoma patient harboring SQSTM1-NTRK1 fusion Surg Case Rep 2024 10 171 PMC11252091

[10] Cheng Y,Chen X,Feng L.et al. Stromal architecture and fibroblast subpopulations with opposing effects on outcomes in hepatocellular carcinoma Cell Discov 2025 11 1 PMC11772884